Singapore’s manufacturing sector has been growing rapidly with, in terms of the drug industry, Novartis, Roche and Pfizer being just some of the most high profile firms to have invested there in recent years.
These trends were a key motivation for BTS’ new office according to company spokesman Arnold Rajathurai who told in-PharmaTechnologist the firm had followed “potential customers towards this region.”
Dr Rajathurai explained that: “BTS is starting its South East Asia office … to have a closer look into the growing market in this area especially in [pharmaceutical and chemical manufacturing.”
He went on to say that the new regional base will provide manufacturers with “engineering and other consulting services like energy efficiency checks and environmental technologies.”
BTS, which is a subsidiary of German drugmaker Bayer, already has an extensive network of engineering consulting offices, spanning Europe, South America, the US and the Middle East.
In Asia, BTS’ regional headquarters is in Shanghai, China that will managed operations at both the new Singapore office and the unit in Mumbai India that the firm recently set up.
Lonza micro reactors
The other major part of the Singapore office’s core business, according to Rajathurai, will be the provision of specialist microreaction development and production technology to drug and chemicals firms.
Last month BTS’ Ehrfeld Mikrotechnik subsidiary signed andeal with Lonza under which it will act as exclusive worldwide manufacturer and distributor of the Swiss firms’ Development Mircoreactor and Advanced Production Microreactor platforms.
The technologies, which were recently awarded the Sandmeyer prize for industrial chemistry and the Profile in Sustainability award at Informex, have numerous applications in drug production, particularly in the biotechnology field.